TET1 and cancer: Even after adjusted for confounding factors, including age, sex, cancer type, MSI status and TMB status, TET1-MUT still independently predicted favorable OS outcomes (Fig. 4a, HR = 0.47 [95% CI, 0.25 to 0.88], adjusted P = 0.019).